High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement
- 2 February 2012
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 119 (5) , 1117-1122
Abstract
High-dose melphalan (HDM) plus stem cell transplantation is an effective treatment for light-chain amyloidosis (AL), but is associated with high treatment-related mortality in patients with cardiac involvement. We studied 187 patients with cardiac involvement with AL who underwent HDM between 1996 and 2008. The median age was 57 years and the median time from diagnosis to HDM was 3.6 months. Half of the patients received reduced-dose melphalan (100-160 mg/m2). The median overall survival (OS) was 66 months, 54 months from diagnosis and HDM, respectively, and 91 patients (49%) were alive at the last follow-up 52 months (median) from HDM. Thirty patients (16%) died within 100 days of transplantation; only low serum albumin predicted early deaths. Overall, hematologic response (HR) and cardiac responses were seen in 66% and 41% of patients, respectively. The median OS for patients with and without HR was not reached and 22 months, respectively (P < .01); and for those with any decrease and no decrease in N-terminal-pro-brain natriuretic peptide was not reached and 26 months, respectively (P < .01). In multivariate analysis of baseline factors, only reduced-dose melphalan predicted shorter OS. HDM is feasible in patients with cardiac amyloidosis, and achievement of HR and organ response is associated with improved survival.Keywords
This publication has 25 references indexed in Scilit:
- Changes in serum‐free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosisAmerican Journal of Hematology, 2010
- Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantationBlood, 2004
- Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic AmyloidosisJournal of Clinical Oncology, 2004
- Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantationBlood, 2004
- High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year StudyAnnals of Internal Medicine, 2004
- Stem cell transplantation for the management of primary systemic amyloidosisThe American Journal of Medicine, 2002
- An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosisBone Marrow Transplantation, 2001
- AL amyloidosis: The last 30 yearsAmyloid, 2000
- Prognostic factors for survival and response after high‐dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patientsBritish Journal of Haematology, 1998
- The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvementQJM: An International Journal of Medicine, 1998